Current Proteomics
Title:Meet Our Editorial Board Member
Volume: 14 Issue: 3
Author(s): Molloy M.P
Affiliation:
Export Options
About this article
Cite this article as:
M.P Molloy , Meet Our Editorial Board Member, Current Proteomics 2017; 14 (3) . https://dx.doi.org/10.2174/157016461403170815155405
DOI https://dx.doi.org/10.2174/157016461403170815155405 |
Print ISSN 1570-1646 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6247 |
10
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Platelet-Rich Plasma Induces Mixed Osteogenic/Osteoclastogenic Phenotype in Osteosarcoma SaOS-2 Cells: Role of TGF-Beta
Current Pharmaceutical Biotechnology Design, Synthesis and In Vitro Anti-Cancer Evaluation of Novel Derivatives of 2-(2-Methyl-1,5-diaryl-1H-pyrrol-3-yl)-2-oxo-N-(pyridin-3- yl)acetamide
Medicinal Chemistry Predicting Targeted Polypharmacology for Drug Repositioning and Multi- Target Drug Discovery
Current Medicinal Chemistry Anticancer Therapeutic Strategies Based on CDK Inhibitors
Current Pharmaceutical Design Anticancer Drug Discovery Targeting DNA Hypermethylation
Current Medicinal Chemistry The Urokinase Receptor in the Central Nervous System
CNS & Neurological Disorders - Drug Targets Small Molecule Toxins Targeting Tumor Receptors
Current Pharmaceutical Design Carbon Nanotube: A Versatile Carrier for Various Biomedical Applications
Drug Delivery Letters Flavonoids Overcome Drug Resistance to Cancer Chemotherapy by Epigenetically Modulating Multiple Mechanisms
Current Cancer Drug Targets Current Molecularly Targeting Therapies in NSCLC and Melanoma
Anti-Cancer Agents in Medicinal Chemistry Dasatinib: An Anti-Tumour Agent via Src Inhibition
Current Drug Targets Cancer Targeted Therapy Strategy: The Pathologist’s Perspectives
Current Cancer Drug Targets Targeting ATP7A to Increase the Sensitivity of Neuroblastoma Cells to Retinoid Therapy
Current Cancer Drug Targets Antifolate Inhibitors of Thymidylate Synthase as Anticancer Drugs
Mini-Reviews in Medicinal Chemistry Methionine Aminopeptidases as Potential Targets for Treatment of Gastrointestinal Cancers and other Tumors
Current Drug Targets Aurora B Kinase and Passenger Proteins as Targets for Cancer Therapy
Current Enzyme Inhibition SCF E3 Ubiquitin Ligases as Anticancer Targets
Current Cancer Drug Targets Organoselenium Compounds in Cancer Chemoprevention
Mini-Reviews in Medicinal Chemistry Chemical Space of FLT3 Inhibitors as Potential Anti-AML Drugs
Recent Patents on Anti-Cancer Drug Discovery Drug Design Studies of the Novel Antitumor Targets Carbonic Anhydrase IX and XII
Current Medicinal Chemistry